CRISPR/Cas9 Gene-Editing Therapy CTX001 for Severe Hemoglobinopathies Accepted for Plenary Presentation at the 62nd American Society of Hematology…

ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON, Nov. 04, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data in seven patients from two ongoing Phase 1/2 clinical trials of the investigational CRISPR/Cas9 gene-editing therapy CTX001 in severe hemoglobinopathies has been accepted for an oral presentation during the Plenary Scientific Session at the annual ASH Meeting and Exposition, which will take place virtually from December 5-8, 2020. Haydar Frangoul, M.D., Medical Director of Pediatric Hematology and Oncology at Sarah Cannon Research Institute, HCA Healthcares TriStar Centennial Medical Center, will deliver the presentation on behalf of all the authors on December 6, 2020.

An abstract posted online today includes data from five patients with three months to 15 months of follow-up after CTX001 infusion in the ongoing Phase 1/2 CLIMB-111 trial in transfusion-dependent beta thalassemia (TDT) and data from two patients with three months and 12 months of follow-up in the ongoing Phase 1/2 CLIMB-121 trial in severe sickle cell disease (SCD). Additional data will be presented at ASH, including longer-duration follow-up data for the patients included in the abstract and data for additional patients with greater than three months of follow-up.

CTX001 is being investigated in these two ongoing clinical trials as a potential one-time curative therapy for patients suffering from TDT and severe SCD.

The accepted abstract is now available on the ASH conference website.

About CTX001 CTX001 is an investigational, autologous, ex vivo CRISPR/Cas9 gene-edited therapy that is being evaluated for patients suffering from TDT or severe SCD, in which a patients hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin (HbF; hemoglobin F) in red blood cells. HbF is a form of the oxygen-carrying hemoglobin that is naturally present at birth, which then switches to the adult form of hemoglobin. The elevation of HbF by CTX001 has the potential to alleviate transfusion requirements for TDT patients and reduce painful and debilitating sickle crises for SCD patients.

Based on progress in this program to date, CTX001 has been granted Regenerative Medicine Advanced Therapy (RMAT), Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the U.S. Food and Drug Administration (FDA). CTX001 has also been granted Orphan Drug Designation from the European Commission for both TDT and SCD, as well as Priority Medicines (PRIME) designation from the European Medicines Agency (EMA) for SCD.

CTX001 is being developed under a co-development and co-commercialization agreement between CRISPR Therapeutics and Vertex. Among gene-editing approaches being investigated/evaluated for TDT and SCD, CTX001 is the furthest advanced in clinical development.

About CLIMB-111 The ongoing Phase 1/2 open-label trial, CLIMB-Thal-111, is designed to assess the safety and efficacy of a single dose of CTX001 in patients ages 12 to 35 with TDT. The trial will enroll up to 45 patients and follow patients for approximately two years after infusion. Each patient will be asked to participate in a long-term follow-up trial.

About CLIMB-121 The ongoing Phase 1/2 open-label trial, CLIMB-SCD-121, is designed to assess the safety and efficacy of a single dose of CTX001 in patients ages 12 to 35 with severe SCD. The trial will enroll up to 45 patients and follow patients for approximately two years after infusion. Each patient will be asked to participate in a long-term follow-up trial.

About the Gene-Editing Process in These Trials Patients who enroll in these trials will have their own hematopoietic stem and progenitor cells collected from peripheral blood. The patients cells will be edited using the CRISPR/Cas9 technology. The edited cells, CTX001, will then be infused back into the patient as part of a stem cell transplant, a process which involves, among other things, a patient being treated with myeloablative busulfan conditioning. Patients undergoing stem cell transplants may also encounter side effects (ranging from mild to severe) that are unrelated to the administration of CTX001. Patients will initially be monitored to determine when the edited cells begin to produce mature blood cells, a process known as engraftment. After engraftment, patients will continue to be monitored to track the impact of CTX001 on multiple measures of disease and for safety.

About the CRISPR-Vertex Collaboration CRISPR Therapeutics and Vertex entered into a strategic research collaboration in 2015 focused on the use of CRISPR/Cas9 to discover and develop potential new treatments aimed at the underlying genetic causes of human disease. CTX001 represents the first potential treatment to emerge from the joint research program. CRISPR Therapeutics and Vertex will jointly develop and commercialize CTX001 and equally share all research and development costs and profits worldwide.

About CRISPR Therapeutics CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit http://www.crisprtx.com.

CRISPR Therapeutics Forward-Looking Statement This press release may contain a number of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, as well as statements regarding CRISPR Therapeutics expectations about any or all of the following: (i) the status of clinical trials (including, without limitation, the expected timing of data releases) related to product candidates under development by CRISPR Therapeutics and its collaborators, including expectations regarding the data and plans to present data at the annual ASH meeting and exposition; (ii) the expected benefits of CRISPR Therapeutics collaborations; and (iii) the therapeutic value, development, and commercial potential of CRISPR/Cas9 gene editing technologies and therapies. Without limiting the foregoing, the words believes, anticipates, plans, expects and similar expressions are intended to identify forward-looking statements. You are cautioned that forward-looking statements are inherently uncertain. Although CRISPR Therapeutics believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those projected or suggested in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: the potential for initial and preliminary data from any clinical trial and initial data from a limited number of patients (as is the case with CTX001 at this time) not to be indicative of final trial results; the potential that CTX001 clinical trial results may not be favorable; the potential impacts due to the coronavirus pandemic, such as the timing and progress of clinical trials; that future competitive or other market factors may adversely affect the commercial potential for CTX001; uncertainties regarding the intellectual property protection for CRISPR Therapeutics technology and intellectual property belonging to third parties, and the outcome of proceedings (such as an interference, an opposition or a similar proceeding) involving all or any portion of such intellectual property; and those risks and uncertainties described under the heading "Risk Factors" in CRISPR Therapeutics most recent annual report on Form 10-K, quarterly report on Form 10-Q, and in any other subsequent filings made by CRISPR Therapeutics with the U.S. Securities and Exchange Commission, which are available on the SEC's website at http://www.sec.gov. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. CRISPR Therapeutics disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.

CRISPR THERAPEUTICS word mark and design logo and CTX001 are trademarks and registered trademarks of CRISPR Therapeutics AG. All other trademarks and registered trademarks are the property of their respective owners.

About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) a rare, life-threatening genetic disease and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases. In addition, Vertex has a rapidly expanding pipeline of genetic and cell therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes mellitus.

Founded in 1989 in Cambridge, Mass., Vertex's global headquarters is now located in Boston's Innovation District and its international headquarters is in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry's top places to work, including 11 consecutive years on Science magazine's Top Employers list and a best place to work for LGBTQ equality by the Human Rights Campaign. For company updates and to learn more about Vertex's history of innovation, visit http://www.vrtx.com or follow us on Facebook, Twitter, LinkedIn, YouTube and Instagram.

Vertex Special Note Regarding Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding the expectations and plans to present data at the annual ASH meeting and exposition, the development, including expected timeline for development, and potential benefits of CTX001, our plans and expectations for our clinical trials and clinical trial sites, and the status of our clinical trials of our product candidates under development by us and our collaborators, including activities at the clinical trial sites and potential outcomes. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that data from the company's development programs, including its programs with its collaborators, may not support registration or further development of its compounds due to safety, efficacy or other reasons, and other risks listed under Risk Factors in Vertex's most recent annual report and subsequent quarterly reports filed with the Securities and Exchange Commission and available through the company's website at http://www.vrtx.com. You should not place undue reliance on these statements or the scientific data presented. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.

(VRTX-GEN)

CRISPR Therapeutics Investor Contact: Susan Kim, +1 617-307-7503 susan.kim@crisprtx.com

CRISPR Therapeutics Media Contact: Rachel Eides WCG on behalf of CRISPR +1 617-337-4167 reides@wcgworld.com

Vertex Pharmaceuticals Incorporated Investors: Michael Partridge, +1 617-341-6108 or Zach Barber, +1 617-341-6470 or Brenda Eustace, +1 617-341-6187

Media: mediainfo@vrtx.com or U.S.: +1 617-341-6992 or Heather Nichols: +1 617-839-3607 or International: +44 20 3204 5275

Go here to read the rest:
CRISPR/Cas9 Gene-Editing Therapy CTX001 for Severe Hemoglobinopathies Accepted for Plenary Presentation at the 62nd American Society of Hematology...

XNK Therapeutics receives US orphan drug status for NK cell-based immunotherapy in multiple myeloma – BioSpace

STOCKHOLM, Nov. 4, 2020 /PRNewswire/ --XNK Therapeutics AB ("XNK") today announced it has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for its leading investigational drug candidate in the treatment of multiple myeloma (MM).

Receiving ODD status from the FDA for the treatment of multiple myeloma is a critical next step for the development of XNK's leading investigational drug candidate. XNK has already received ODD status in the EU.

"Obtaining an ODD by the FDA is a significant milestone for XNK and our goal of taking the present drug candidate to the next level," said Johan Liwing, CEO of XNK Therapeutics. "This is the starting point for us to expand clinical development into the most important market globally for cancer treatment."

XNK has already completed its first-in-human Phase I/II clinical trial (ACP-001) in multiple myeloma at the Karolinska University Hospital in Stockholm, Sweden, showing a very good safety profile, and promising efficacy data. The company is continuing the clinical development in multiple myeloma in Europe and plans to initiate a Phase II clinical trial in the near future.

For more information, please contact:

Johan Liwing, CEO, XNK Therapeutics Tel: +46706 70 36 75 E-mail: johan.liwing@xnktherapeutics.com

About XNK Therapeutics AB

XNK Therapeutics is a clinical stage, immunotherapy company focusing its efforts on preventing and treating cancer by developing novel NK cell-based therapies. The company has established a leadership position in the clinical development and manufacture of autologousNK cell-based products using its proprietary technology platform. The company's platform technology and leading investigational drug candidate have ideal properties for targeting cancers, including settings where allogeneic cell products are not readily applicable. It is foreseen that the product will bring a critical component to tomorrow's cancer treatment strategies. XNK Therapeutics is headquartered in Stockholm, Sweden. For more info, please visit http://www.xnktherapeutics.com.

About XNK Therapeutics's technology platform

The platform has ideal properties to produce autologous NK cell-based drug candidates for targeting malignant diseases across a wide range of indications in mono- and combination therapy. It encompasses a unique closed manufacturing system for development of the NK cell-based products. The process includes a selective expansion and activation of NK cells from peripheral blood of patients with cancer. The product is produced in less than three weeks. It is delivered to the clinic upon need, where the product is thawed and infused into the patient without any further processing. The product has demonstrated an up to 10-year stability in liquid nitrogen. The assets of XNK Therapeutics are protected by patents in the US, Europe and certain other jurisdictions. Additional patent applications have been filed.

About Our Therapy

The leading drug candidate from XNK Therapeutics' technology platform was previously clinically tested in a first-in-human Phase I/II clinical trial (ACP-001). The study was performed at the Karolinska University Hospital, Stockholm, Sweden in a setting of consolidation treatment following high dose stem cell transplantation in patients newly diagnosed with multiple myeloma. The study was an open, single-arm, triple escalating dose/patient clinical trial with the primary objective of studying the product's safety and tolerability. In the study, the therapy showed a very good safety profile, and promising efficacy data. XNK Therapeutics is continuing its clinical development in multiple myeloma and plans to initiate a Phase II clinical trial in the near future.

About multiple myeloma

Multiple myeloma, the company's first target, is the third most frequent hematological malignancy worldwide. Multiple myeloma treatment has improved over the last two decades with the development and introduction of new agents leading to more effective treatments. Still, it remains a fatal disease in the majority of cases.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/xnk-therapeutics-ab/r/xnk-therapeutics-receives-us-orphan-drug-status-for-nk-cell-based-immunotherapy-in-multiple-myeloma,c3231231

The following files are available for download:

View original content:http://www.prnewswire.com/news-releases/xnk-therapeutics-receives-us-orphan-drug-status-for-nk-cell-based-immunotherapy-in-multiple-myeloma-301166343.html

SOURCE XNK Therapeutics AB

Go here to read the rest:
XNK Therapeutics receives US orphan drug status for NK cell-based immunotherapy in multiple myeloma - BioSpace

Gamida Cell Announces Data to Be Presented at 62nd ASH Annual Virtual Meeting – Business Wire

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, today announced that updated data from the ongoing Phase 1 clinical study of GDA-201, an investigational, natural killer (NK) cell-based cancer immunotherapy for the treatment of patients with non-Hodgkin lymphoma, will be presented in an oral presentation at the American Society of Hematology (ASH) 62nd Annual Meeting, which is being held virtually from December 5-8, 2020. NK cell immunotherapies are thought to offer tremendous potential for transforming the care of hematologic malignancies. Gamida Cell is pioneering a novel approach that harnesses the power of its cell expansion technology, which uniquely improves antibody-dependent cellular cytotoxicity (ADCC) and tumor targeting of NK cells.

Additionally, new data from the ongoing Phase 1/2 study of omidubicel in patients with severe aplastic anemia will be shared in a poster presentation during the meeting. Omidubicel is an investigational advanced cell therapy in development as a potential life-saving treatment option for patients in need of a bone marrow transplant.

Omidubicel is also being evaluated in a Phase 3 study in patients with hematologic malignancies. Earlier this year, Gamida Cell reported that its Phase 3 study of omidubicel met its primary endpoint, demonstrating a highly statistically significant reduction in time to neutrophil engraftment, a key milestone in recovery from a stem cell transplant. Last month, Gamida Cell also reported that all three secondary endpoints for the study demonstrated statistical significance. The secondary endpoints in the study include outcomes for: platelet engraftment, infections and hospitalizations.

Details about the ASH presentations are as follows:

Title: Results of a Phase 1 Trial of GDA-201, Nicotinamide-Expanded Allogeneic Natural Killer (NK) Cells in Patients with Refractory Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma Abstract Number: 63 Lead Author: Veronika Bachanova, M.D., Ph.D., Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN Time: Saturday, December 5, 2020, 7:30 a.m. 9:00 a.m. PT (session time) and 7:30 a.m. PT (presentation)

Title: Rapid Engraftment, Immune Recovery, and Resolution of Transfusion Dependence in Treatment-Refractory Severe Aplastic Anemia Following Transplantation with Ex Vivo Expanded Umbilical Cord Blood (Omidubicel) Abstract Number: 1531 Lead Author: Mohamed Samour, M.D., Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, MD Time: Saturday, December 5, 2020, 7:00 a.m. 3:30 p.m. PT

About Omidubicel

Omidubicel is an advanced cell therapy under development as a potential life-saving allogeneic hematopoietic stem cell (bone marrow) transplant solution for patients with hematologic malignancies (blood cancers). In both Phase 1/2 and Phase 3 clinical studies (NCT01816230, NCT02730299), omidubicel demonstrated rapid and durable time to engraftment and was generally well tolerated. Omidubicel is also being evaluated in a Phase 1/2 clinical study in patients with severe aplastic anemia (NCT03173937). The aplastic anemia investigational new drug application is currently filed with the FDA under the brand name CordIn, which is the same investigational development candidate as omidubicel. For more information on clinical trials of omidubicel, please visit http://www.clinicaltrials.gov.

Omidubicel is an investigational therapy, and its safety and efficacy have not been evaluated by the U.S. Food and Drug Administration or any other health authority.

About GDA-201

Gamida Cell applied the capabilities of its NAM-based cell expansion technology to develop GDA-201, an innate natural killer (NK) cell immunotherapy for the treatment of hematologic and solid tumors in combination with standard of care antibody therapies. GDA-201 addresses key limitations of NK cells by increasing the cytotoxicity and in vivo retention and proliferation in the bone marrow and lymphoid organs of NK cells expanded in culture. GDA-201 is in Phase 1 development through an investigator-sponsored study in patients with refractory non-Hodgkin lymphoma and multiple myeloma.1

GDA-201 is an investigational therapy, and its safety and efficacy has not been evaluated by the U.S. Food and Drug Administration or any other health authority.

About Gamida Cell

Gamida Cell is an advanced cell therapy company committed to cures for patients with blood cancers and serious blood diseases. We harness our cell expansion platform to create therapies with the potential to redefine standards of care in areas of serious medical need. For additional information, please visit http://www.gamida-cell.com or follow Gamida Cell on LinkedIn or Twitter at @GamidaCellTx.

Cautionary Note Regarding Forward Looking Statements

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to the potential of NK cell immunotherapies and the continuation of Gamida Cells clinical programs, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to the scope and progress of Gamida Cells clinical trials and other clinical, scientific, regulatory and technical developments. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section of Gamida Cells public filing on Form 20-F, filed with the SEC on February 26, 2020, and other filings that Gamida Cell makes with the SEC from time to time (which are available at http://www.sec.gov), the events and circumstances discussed in such forward-looking statements may not occur, and Gamida Cells actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are based on information available to Gamida Cell as of the date of this release.

More:
Gamida Cell Announces Data to Be Presented at 62nd ASH Annual Virtual Meeting - Business Wire

Global Autologous Cell Therapy Market will Showcase Neutral Impact During 2020-2024 | Use of Biomass as a Fuel in Boiler to Boost Market Growth |…

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the global autologous cell therapy market and it is poised to grow by USD 1.97 billion during 2020-2024, progressing at a CAGR of almost 22% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Technavios in-depth research has all your needs covered as our research reports include all foreseeable market scenarios, including pre- & post-COVID-19 analysis. Download Latest Free Sample Report on COVID-19 Analysis

The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Bayer AG, Brainstorm Cell Therapeutics Inc., Daiichi Sankyo Co. Ltd., FUJIFILM Holdings Corp., Holostem Terapie Avanzate Srl, Osiris Therapeutics Inc., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Sumitomo Chemical Co. Ltd., and Vericel Corp. are some of the major market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

The use of biomass as a fuel in boilers has been instrumental in driving the growth of the market.

Technavio's custom research reports offer detailed insights on the impact of COVID-19 at an industry level, a regional level, and subsequent supply chain operations. This customized report will also help clients keep up with new product launches in direct & indirect COVID-19 related markets, upcoming vaccines and pipeline analysis, and significant developments in vendor operations and government regulations. Download a Free Sample Report on COVID-19 Impacts

Autologous Cell Therapy Market 2020-2024: Segmentation

Autologous Cell Therapy Market is segmented as below:

Autologous Cell Therapy Market 2020-2024: Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. The autologous cell therapy market report covers the following areas:

This study identifies the increasing demand for effective drugs for cardiac and degenerative disorders as one of the prime reasons driving the Autologous Cell Therapy Market growth during the next few years.

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Technavios in-depth research has direct and indirect COVID-19 impacted market research reports.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Autologous Cell Therapy Market 2020-2024: Key Highlights

Table of Contents:

Executive Summary

Market Landscape

Market Sizing

Five Forces Analysis

Market Segmentation by Therapy

Customer landscape

Geographic Landscape

Drivers, Challenges, and Trends

Vendor Landscape

Vendors covered

Appendix

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Read the original here:
Global Autologous Cell Therapy Market will Showcase Neutral Impact During 2020-2024 | Use of Biomass as a Fuel in Boiler to Boost Market Growth |...

Animal Stem Cell Therapy Market Size 2020-2026 Review, Key Findings, Growth Strategy, Developing Technologies, Trends And Global Forecast By Regions -…

The Animal Stem Cell Therapy market report provides a detailed analysis of the emerging trends, opportunities, and as well as the challenges in the market. This extensive report sheds light on the latest developments, market drivers, and competitive analysis to help the new entrants and emerging players to make crucial decisions.

Besides this, the market research report presents insights on consumer behavior, regulatory policies, and supply & demand scenario to provide a holistic view of the market. The primitive aim of the report is to represent the critical data and figures of the market concisely and layout top winning strategies to aid industry players to leverage their market position.

Get Free Sample Report + All Related Graphs & Charts: https://industrygrowthinsights.com/request-sample/?reportId=171131

The dedicated research team has included Porters Five Point Force analysis to tailor the Global Animal Stem Cell Therapy Market. They have conducted interviews with industry experts to provide accurate predictions and better insights in a detailed manner. The research report covers the latest advancements that have overhauled the market dynamics while examined the threats which has impacted the overall market.

Key Answers Captured in the Study are

Complete Purchase of Latest Version Global Animal Stem Cell Therapy Market Study with COVID-19 Impact Analysis: https://industrygrowthinsights.com/checkout/?reportId=171131

Important Features that are under offering & key highlights of the report:

Detailed overview of Animal Stem Cell Therapy

Changing market dynamics of the industry

In-depth market segmentation by Type, Application, etc.

Historical, current, and projected market size in terms of volume and value

Recent industry trends and developments

Competitive landscape of Animal Stem Cell Therapy

Strategies of key players and product offerings

Potential and niche segments/regions exhibiting promising growth

A neutral perspective towards Animal Stem Cell Therapy performance

Market players information to sustain and enhance their footprint

Ask for the discount @ https://industrygrowthinsights.com/ask-for-discount/?reportId=171131

Research Objectives

To analyze and forecast the Worldwide Animal Stem Cell Therapy, in terms of value and volume.

Which segment has the potential to gain the highest market share?

To help decision-makers from a new offer perspective and benchmark existing marketing strategy.

Correlate cost structure historical data with key business segments.

Analyze marketing contribution and customer acquisition by up-selling and cross-selling.

Identifying Influencing factors keeping Worldwide Animal Stem Cell Therapy Intense, factored with periodic analysis of CR4 & CR8 concentration ratio & HHI Index.

Important Features that are under offering & key highlights of the report:

1) Does the study cover COVID-19 Impact Analysis and its effect on Growth %?

Yes, the overall industry has seen quite a big impact due to slowdown and shutdown in the production line & supply chain. The study covers a separate qualitative chapter on COVID-19 Impact analysis. Additionally, it also provides before and after the scenario of COVID-19 on sales growth & market size estimation to better analyze the exact scenario of the industry.

2) How companies are selected or profiled in the report?

List of some players that are profiled in the report include:

Medivet Biologics LLC VETSTEM BIOPHARMA J-ARM U.S. Stem Cell, Inc VetCell Therapeutics Celavet Inc. Magellan Stem Cells Kintaro Cells Power Animal Stem Care Animal Cell Therapies Cell Therapy Sciences Animacel

Usually, we follow NAICS Industry standards and validate company profile with product mapping to filter relevant Industry players, furthermore the list is sorted to come up with a sample size of at least 50 to 100 companies having greater topline value to get their segment revenue for market estimation.

** List of companies mentioned may vary in the final report subject to Name Change / Merger etc.

3) Can we add or profiled a new company as per our needs?

Yes, we can add or profile a new company as per client need in the report, provided it is available in our coverage list as mentioned in answer to Question 1 and after feasibility run, final confirmation will be provided by the research team checking the constraints related to the difficulty of survey.

4) Can we narrow the available business segments?

Yes, depending upon the data availability and feasibility check by our Research Analyst, a further breakdown in business segments by end-use application or product type can be provided (If applicable) by Revenue Size or Volume*.

Animal Stem Cell Therapy market segmentation

The Study is segmented by following Product Type:

Dogs Horses Others

Major applications/end-users industry are as follows:

Veterinary Hospitals Research Organizations

5) Can a specific country of interest be added? What all regional segmentation covered?

Yes, Country-level splits can be modified in the study as per objectives. Currently, the research report gives special attention and focus on the following regions:

North America [United States, Canada, Mexico], Asia-Pacific [China, India, Japan, South Korea, Australia, Indonesia, Malaysia, Philippines, Thailand, Vietnam], Europe [Germany, France, UK, Italy, Russia, Rest of Europe], South America [Brazil, Argentina, Rest of South America], Middle East & Africa [GCC Countries, Turkey, Egypt, South Africa, Rest of the Middle East & Africa]

** One country of specific interest can be included at no added cost. For inclusion of more regional segment quotes will vary.

Get on the call with our research analyst if you have any particular doubts before buying the report @ https://industrygrowthinsights.com/enquiry-before-buying/?reportId=171131

About Us:

Our reports are more than just research reports to us. They are tools that enable us to maintain long-term relationships with our clients whom we honor and cherish. Our clients business growth is integral for not only them but also us. This is what differentiates us from other market research companies.

At IGI, we provide our expertise and guideline for success. Our team of efficient and experienced researchers and consultants provide progressive market intelligence reports that are accurate, authentic, and in-depth. This empowers the clients to make well-informed decisions.

Moreover, we offer market intelligence studies, ensuring relevant and fact-based research across a range of industries including chemicals and materials, energy, automobile, healthcare, consumer goods, and technology. Our deep understanding of many business environments across industries such as those mentioned above allows us to deliver tailor-made reports.

Contact Us:

Alex Mathews Head of Business Development Phone No.: +1 909 545 6473 Email sales@industrygrowthinsights.com Website https://industrygrowthinsights.com Address 500 East E Street, Ontario, CA 91764, United States.

More:
Animal Stem Cell Therapy Market Size 2020-2026 Review, Key Findings, Growth Strategy, Developing Technologies, Trends And Global Forecast By Regions -...

Covid-19 Impact On Animal Stem Cell Therapy Market Analysis, Trends, Share, Size, Consumption 2020 2026 | MediVet Biologic, VETSTEM BIOPHARMA, J-ARM,…

Chicago, United States: Global Animal Stem Cell Therapy Market Report 2020, Forecast to 2026, The report focuses on encompassing several factors such as global distribution, manufacturers, and various regions. The report has summed up industry analysis size, share, application, and statistics associated with the global Peptide Synthesis market. The report delivers an in-depth competitive landscape, Growth opportunities, market share coupled with product type and applications. The report also estimates comprehensive market revenue along with Growth patterns, and the overall volume of the market.

Crucial information and forecast statistics covered in the Animal Stem Cell Therapy Market report will arm both existing and emerging market players with necessary insights to craft long-term strategies as well as maintain business continuity during a crisis such as the ongoing COVID-19 pandemic.

Key players covered in the report include: MediVet Biologic, VETSTEM BIOPHARMA, J-ARM, Celavet, Magellan Stem Cells, U.S. Stem Cell, Cells Power Japan, ANIMAL CELL THERAPIES, Animal Care Stem, Cell Therapy Sciences, VetCell Therapeutics, Animacel, Aratana Therapeutics

Request for Sample Report (Including COVID19 Impact Analysis, full TOC, Tables and Figures) of Animal Stem Cell Therapy Market @ https://www.reporthive.com/request_sample/2470743

NOTE: Due to the pandemic, we have included a special section on the Impact of COVID 19 on the Animal Stem Cell Therapy Market which would mention How the Covid-19 is affecting the Animal Stem Cell Therapy Industry, Market Trends and Potential Opportunities in the COVID-19 Landscape, Covid-19 Impact on Key Regions and Proposal for Animal Stem Cell Therapy Players to Combat Covid-19 Impact. Valuable information covered in the Animal Stem Cell Therapy Market report has been segregated into key segments and sub-segments.

By Service type Dogs Horses Others

By End use Veterinary Hospitals Research Organizations

This report can be dispatched within 24-48 Hours.

Animal Stem Cell Therapy Market: Competition Analysis

The Report Hive Research study presents a comprehensive analysis of global, regional, and country-level players active in the Animal Stem Cell Therapy Market. Competitive information detailed in the Animal Stem Cell Therapy Market report has been based on innovative product launches, distribution channels, local networks, industrial penetration, production methods, and revenue generation of each market player.

Important Questions Answered in the Animal Stem Cell Therapy Market Report

Key Offerings of the Report

>>>>Get Full Customize Report @ https://www.reporthive.com/request_customization/2470743

Animal stem cell therapy is a usage of animals stem cell to treat a disease or disorder. The ability of stem cell is to divide and differentiate into a cell with specialized function useful for repairing body tissues damaged by injury or disease. The animal stem cell therapy process involves three steps which include collection of stem cell sample from animals and preparing the sample to concentrate the stem cells. Finally, the therapy includes transferring the stem cells into the injured site for treatment. Animal stem cell therapy increases the expectancy of life in animals with no side effects. It is available for the treatment of arthritis, degenerative joint disorders, tendon, and ligaments injuries in animals. Stem cell therapy is most often used to treat dogs, cats, and horses. But recent developments made it possible to use animal stem cell therapy in tiger, pig, etc. Present animal stem cell therapy is studied in treatments of the inflammatory bowel, kidney, liver, heart and immune-mediated diseases respectively. The global Animal Stem Cell Therapy market is expected to reach xxx Million USD by 2025, with a CAGR of xx% from 2020 to 2025.

Why Go For Report Hive Research?

Report Hive Research delivers strategic market research reports, statistical surveys, industry analysis and forecast data on products and services, markets and companies. Our clientele ranges mix of global business leaders, government organizations, SMEs, individuals and Start-ups, top management consulting firms, universities, etc. Our library of 700,000 + reports targets high Growth emerging markets in the USA, Europe Middle East, Africa, Asia Pacific covering industries like IT, Telecom, Semiconductor, Chemical, Healthcare, Pharmaceutical, Energy and Power, Manufacturing, Automotive and Transportation, Food and Beverages, etc. This large collection of insightful reports assists clients to stay ahead of time and competition. We help in business decision-making on aspects such as market entry strategies, market sizing, market share analysis, sales and revenue, technology trends, competitive analysis, product portfolio, and application analysis, etc.

Get in Touch with Us :

Report Hive Research

500, North Michigan Avenue,

Suite 6014,

Chicago, IL 60611,

United States

Website: : https://www.reporthive.com

Email: [emailprotected]

Follow this link:
Covid-19 Impact On Animal Stem Cell Therapy Market Analysis, Trends, Share, Size, Consumption 2020 2026 | MediVet Biologic, VETSTEM BIOPHARMA, J-ARM,...

Stem Cell Therapy for Autism: Effects & Costs in 2020

As a parent of an autistic child, you want to see your child live to their fullest potential. When a clinic offers stem cell therapy for autism, which seems like a miracle cure, you may want to immediately pursue it. You want to try anything that could help your child function better in the world.

Many clinics offer stem cell therapies to treat a range of conditions, including autism. While there is some important new medical research being conducted on how well stem cells work in mitigating symptoms of autism, none of these treatments have received FDA approval.

In 2020, these stem cell therapy treatments are not considered safe for children with autism.

Stem cell therapy is a new field in medicine that offers huge potential to treat conditions that have few other options.

However, there are questionable operations claiming to use stem cells to rejuvenate, improve, or even cure conditions that have no immediate cure. It can be difficult to know the difference between what is advertised as a legitimate medical treatment and what might actually be harmful for someone with a long-term condition like autism.

Stem cells are sometimes referred to as the bodys master cells because they are like a blank slate for creating new cells. Bones, organs, blood, and brain cells all start as stem cells.

In some instances, these cells might regenerate, restore, or even replace these tissues. This means that, when used in some medical treatments, stem cells have the potential to fix many underlying issues. The United States Food and Drug Administration (FDA) regulates stem cell products in the U.S.

The FDA has approved limited use of stem cells in treatments for some types of cancer or disorders of blood and bone marrow. As more stem cell treatments are tested in clinical trials in tightly controlled human studies, more conditions may appear to have prescribed stem cell treatments associated with them. While these clinical trials are very important and can help study participants, few of these clinical trials lead to cures or even therapies to manage the condition.

Before pursuing a clinic offering stem cell therapy, check whether the practitioners have received FDA approval for the treatment.

Autism is one of the conditions that could potentially one day benefit from stem cell treatments. This developmental disorder mainly impacts behavior, socializing, communication, and cognition.

Some anecdotal evidence exists that clinics offering unapproved stem cell treatments benefit people with autism; however, there is very little evidence through medical studies that this is possible. Currently, the best treatment for autism is behavior therapy like applied behavior analysis (ABA).

There are several clinics offering stem cell treatments for a range of conditions, including autism, joint pain from any source, and multiple sclerosis. The cells used in treatment tend to come from fat cells donated or sold after liposuction treatment.

Typically, these cells are autologous , meaning they are extracted from the patient to create the stem cell therapy and then infused back into the patient. Some clinics use bone marrow or umbilical cord tissues, which come from different donors who are not genetically related to the person receiving treatment.

While clinics report happy testimonials from people who undergo these therapies, it is important to note that many of the reported benefits are associated with conditions that have symptoms that fluctuate over time. For example, arthritis symptoms may come and go, with flareups of pain and inflammation persisting for several weeks or months and then going away as the condition temporarily goes into remission.

Children with autism tend to be diagnosed at a young age, often around 2 or 3 years old . It is well established that autistic children should receive evidence-based treatment like ABA therapy to reduce later problems with communication, cognition, and socializing. The efficacy of many new treatments for autism is unproven.

It can be difficult for medical studies into any therapy, including a new treatment like stem cell injections, to definitively know if improvements in symptoms are associated with the therapy or with natural developmental changes that can lead to improvements in autism symptoms as the child gets older. More research is needed to solidify conclusions, and currently, the research into stem cell therapy for autism is lacking.

There are concerns that companies may be preying on autistic parents , offering the hope of a cure for autism or a dramatic improvement in symptoms that just hasnt been proven. Some stem cell therapy companies charge tens of thousands of dollars for this treatment. Regulators warn that the treatments may be illegal, unsafe, and potentially harmful.

While parents should be wary of commercial stem cell therapy offerings, studies into the practice are ongoing.

As of a 2018 meta-survey , there were several clinical trials using stem cells to manage autism symptoms.

Overall Improvement With Potential for Adverse Effects

For example, one study followed 32 school-aged participants whose ages averaged about 10.5 years old. The group received bone-marrow-derived mononuclear cell (BMMNC) transplantation, which uses stem cells from blood. The protocol involved the intrathecal cellular therapy as well as other important therapies for autism, including occupational, sensory integration, psychological, dietary, and speech therapy.

During the course of the study, three participants developed seizures, and a small percentage of the group developed mild increases in hyperactivity as a result of the stem cell treatment. However, as a group, there were noted improvements in social relationships and reciprocity like smiling and eye contact; thinking, attention, and cognition; and speech and language patterns and usage. There was also a decrease in inappropriate emotional responses, self-stimulating behaviors, excitement or agitation for no clear reason, and exaggerated emotional responses.

While there were some adverse side effects, many improvements were also seen in the small group.

More Benefits for Nonverbal Children With Higher IQs

Another clinical trial examined a group of diagnosed autistic children between the ages of 2 and 7 to see if autologous umbilical cord blood (AUCB) transplantation could improve some autism symptoms. Subjects were randomly divided into two groups, with one receiving the stem cell transplant and the other receiving saline injections.

At a six-month follow-up, the group who received infusions had better socialization, communication, and adaptive behavior scores compared to the control group. The improvement was sustained at a one-year follow-up.

Unlike some other studies, nonverbal children with higher IQs seemed to benefit the most from this type of stem cell infusion. The researchers stated that the improvements could also be associated with natural development as the children entered preschool.

The Necessity of FDA Approval

There have been three other major stem cell studies involving children with autism, but they have all had a wide variance in the treatments used, study participants, how outcomes were measured, and even how the studies were designed.

More importantly, clinical trials do not prove that stem cell therapies work. Pursuing any that do not have FDA approval could cause harm to your child. Problems With Getting Stem Cell Therapy for Autism in 2020

While you want to do everything possible to help your child, there are some serious risks with attempting unapproved treatments like stem cell therapy. These risks remain even if the clinic is managed by medical personnel, has a good reputation, or appears clean.

If you participate in an unproven treatment that is not FDA-approved, like stem cell therapy, you could put your child at risk for:

Infections.

Tumors.

Inflammatory conditions due to unfamiliar cells.

Skin irritation at injection sites.

Damage to the central nervous system when using lumbar punctures.

Because these clinics are not real medical clinics , they dont have licenses or oversight. You will not receive any health insurance coverage for these treatments as they are considered experimental.

These clinics are essentially boutique operations. They often charge a lot of money while falsely raising your hopes about the outcome. Parents suffer through grief and frustration when the treatment doesnt work, and they are left with a major financial setback.

The best way to help your child when they receive an autism diagnosis is to pursue evidence-based treatments that are recommended by your pediatrician and other specialists.

Treatment will most likely involve behavior therapy like ABA. This therapy has been shown over decades of practice and numerous medical studies to help people with autism manage behaviors associated with the condition. Speech therapy and occupational therapy are also commonly part of an autism treatment plan, depending on the severity of the disorder and the childs specific needs.

Complementary treatments like art therapy or music therapy can round out a treatment plan. These creative therapies help to improve behaviors, socializing, communication, and motor skills.

In 2020, there is no known cure for autism . While it can be tempting to pursue any therapy that is promising a miracle treatment, be aware that these claims are not based in science. Unfortunately, parents who pursue these false treatments are wasting money and experiencing immense stress.

There are ongoing clinical trials into the efficacy of stem cell therapy for autism, so well learn more about this possibility in the coming years. Until then, stick with therapies your treatment team recommends. This will ensure the safety and progress of your child.

Read more:
Stem Cell Therapy for Autism: Effects & Costs in 2020

Optimal Health: Cutting Edge Restorative Treatments Cityview – Knoxville City View

For 36 years the professionals at Optimal Health have served the people of the greater Knoxville area. Licensed chiropractor and founder J. Scott Brown and his family established their first clinic in West Knoxville. As his family grew so did Dr. Browns vision. He began to bring on medical doctors, nurse practitioners, and physical rehabilitation professionals, all trained in the most cutting-edge treatments for acute and chronic pain. His practice evolved to become one of the largest integrated medical groups in Knoxville, with four locations in the greater Knoxville area, the newest of which is in Turkey Creek. Integrated Medical Optimal Health in Turkey Creek will offer the same integrated medical treatments as the other three locations, but they have just launched a new, cutting-edge pain management treatment called RP Softwave. It uses gentle radial pulse technology to penetrate deep into the soft tissue area of any joint in the body to relieve pain. Patients typically feel relief after the first treatment.

Dr. Brown has a heart for people and wants to see them live their best lives. Hes wants to help them to fully rehabilitate and regenerate naturally. Having been at the forefront of cutting-edge medical advancements and technologies, in early 2019 the family branched out again and opened Optimal Health Regenerative Aesthetics Medical, which is Knoxvilles only full-service regenerative medicine facility.

He identified ways to help people achieve optimal health through regenerative therapies rather than using traditional methods such as surgery or pain medications. The new practice, Optimal Health Regenerative Aesthetics Medical, in Turkey Creek, uses proven, safe regenerative therapies to restore and repair tissue in the joints as well as to treat other inherited or acquired, acute or chronic conditions. They offer a full range of regenerative services. One of their more sought-after services is stem cell therapy for joint repair. Stem cell therapy uses growth factors to repair and rebuild damaged tissue.

They also offer treatments for vaginal rejuvenation and erectile dysfunction. Many of their female patients have overcome urinary incontinence with the revolutionary O-Shot. As one of only four providers of the innovative GAINSwave erectile dysfunction treatment, Optimal Health has provided results for hundreds of men using this treatment combined with regenerative therapies such as the P-shot for truly life-changing results.

Their medical staff also oversees and provides nutritional counseling through a variety of medical weight loss options. They provide regenerative facial aesthetics using the latest innovative practices and equipment such as combining PRP with micro-needling, also known as the Vampire Facial. The clinics licensed aesthetician begins each consultation with a comprehensive facial scan using the PEAR facial scanner. Optimal Health is the only aesthetics clinic in East Tennessee with this technology. The scan can pinpoint with great accuracy the age of your skin as well as help to identify areas that may need immediate protection or treatment. Optimal Health is also known as the Tennessee Center for Excellence as they are the only provider in the state of Tennessee with exclusive rights for the minimally-invasive hair restoration treatment, SmartGraft. Developed by physicians, medical scientists and engineers, SmartGraft allows Optimal Health to perform hair restoration procedures safely and rapidly while delivering natural, permanent results.

The doctors and other providers at Optimal Health have decades of practice in the fields of physical and regenerative medicine. With a well-rounded knowledge of the human body, medically and holistically, the staff at Optimal Health provide the most effective, non-invasive wellness, aesthetics, and pain management services available. At Optimal Health they love to say, You only live once, so take care of yourself! #YOLOTCOY

11668 Parkside Drive

865.288.4200

Knoxvilleoptimalhealth.com

11660 Parkside Drive

865.288.4300

2905 Tazewell Pike

8906 Kingston Pike

217 N. North Calderwood Street, Alcoa

865-690-1455

Integratedmedicaltn.com

Matt cut his writing teeth at NY ad agencies selling colas, credit cards, frozen confections and more for companies like Sealtest, Coke, and American Express. Over the course of the past few decades, he has made the switch from selling to storytelling, and can spend his days doing the two things he loves most; learning and writing. When not writing, Matt keeps pretty busy simply trying to keep up with his four daughters, three cats, two dogs, and a guinea pig named "Rosie." Luckily, his wife is there to help keep him sane.

Link:
Optimal Health: Cutting Edge Restorative Treatments Cityview - Knoxville City View

aHSCT Gets a Boost in US With NMSS Recommendations – Multiple Sclerosis News Today

Is the United States a step closer to approving a form of stem cell transplantation as a treatment for multiple sclerosis? I believe it may be.

Thats because the National Multiple Sclerosis Society (NMSS) has slightly changed its view of autologous hematopoietic stem cell transplantation, or aHSCT.

aHSCT involves removing a patients own stem cells from the blood or bone marrow, using chemotherapy to kill off most of the immune system, and then injecting the stem cells back into the patient. Those stem cells regenerate the immune system, hopefully without any of the rogue immune cells that attack the nervous system and create MS symptoms.

In the past, the National MS Society has failed to make recommendations about how any form of stem cell treatment should be used, at least as far as my research can determine. Now, in an article in JAMA Neurology, a group of neurologists, including members of the NMSS National Medical Advisory Committee, are outlining parts of a stem cell protocol.

The NMSS is now being specific about who might be a candidate for aHSCT:

The National Multiple Sclerosis Society believes that AHSCT may be a useful treatment option for people with relapsing multiple sclerosis who demonstrate substantial breakthrough disease activity (ie, new inflammatory central nervous system lesions and/or clinical relapses) despite treatment with high-efficacy disease-modifying therapy or have contraindications to high-efficacy disease-modifying therapies.

That language seems more aggressive than what the NMSSwrote about an Italian study published earlier this year. In that commentary, the society suggested the procedure might be appropriate for people with secondary progressive MS, and it suggested further study with a larger group:

These results suggest that HSCT might be appropriate in a subgroup of people with SPMS that have significant inflammatory activity as measured by MRI. Further study in larger numbers are needed to understand who among those with secondary progressive MS might benefit from HSCT.

The new guidelines clearly outline which people with relapsing-remitting MS might benefit. They are younger than 50 and have lived with an MS diagnosis for less than 10 years.

The authors recommend that stem cell transplantation be performed in medical centers with substantial experience and expertise. A follow-up regime is proposed, along with the creation of a single database to track people who undergo the procedure. But the article cautions that more research is needed to establish best practices for handling the stem cells and other technical processes.

Some hospitals and clinics in Russia, Mexico, and other locations offer aHSCT to MS patients at a cost of about $50,000. aHSCT also is provided to some MS patients through the U.Ks National Health Service. A list of aHSCT facilities worldwide is available at http://www.hsctstopsms.com.

The authors of the JAMA Neurology article suggest a clinical trial may be the place for someone who wants their MS treated with a stem cell transplant right now. A well-known trial by Dr. Richard Burt shut down about a year ago. However, a trial called BEAT-MS has been enrolling patients at several locations in the U.S. You can find information about other studies at clinicaltrials.gov.

The authors note that joining a trial would assure the patient of quality care with an acceptable protocol and provide the personal satisfaction of knowing they are contributing to answering a very important question for people with MS.

That sounds like a pretty good suggestion to me since the U.S. likely has a long way to go before aHSCT for MS becomes common here, even with the NMSS backing. But its encouraging that finally it is gaining some traction.

Youre invited to follow my personal blog at http://www.themswire.com.

***

Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those of Multiple Sclerosis News Today or its parent company, BioNews, and are intended to spark discussion about issues pertaining to multiple sclerosis.

Diagnosed with MS at age 32 in 1980, Ed has written the MS Wire column for Multiple Sclerosis News Today since August 2016. He presents timely information on MS, blended with personal experiences. Before retiring from full-time work in 2012, Tobias spent more than four decades in broadcast and on-line newsrooms as a manager, reporter, and radio news anchor. Hes won several national broadcast awards. As an MS patient communicator, Ed consults with healthcare and social media companies. Hes the author of Were Not Drunk, We Have MS: A tool kit for people living with multiple sclerosis. Ed and his wife split time between the Washington, D.C. suburbs and Floridas Gulf Coast.

More here:
aHSCT Gets a Boost in US With NMSS Recommendations - Multiple Sclerosis News Today

How pain changes your brain – News – The University of Sydney

Professor Paul Glare at the Pain Management Research Institute.

Opioids are good for acute pain. With chronic pain they only work short to medium term, he says. But after about six months, you become tolerant and have to take bigger doses. Then theres the growing risk of accidental overdose, even accidental death.

For many people though, opioids seem like the only way to numb the pain that constantly attacks them. But do they in fact, numb the pain?

Most people who come off the long term use of opioids realise that the drugs werent doing that much, says Glare. Theyd already stopped working, so the pain without them is often no worse. In fact, the drugs were just messing with their heads. Still its a huge psychological step to let the drugs go.

Gently spoken and with a great sense of compassion for the people he works to help, Glare started his career in palliative care which took him into the area of cancer pain, then pain more generally. Because its difficult to tell people battling chronic pain that there is no satisfactory pharmaceutical answer at this time, the PMRI has a large and active pain education unit.

The Unit offers a Masters of Medicine Pain Management that is also conferred as a Masters of Science for non-medical graduates. It also runs cognitive behavioural therapy classes teaching strategies for rising above the pain.

The classes are challenging, says Glare. But many people who learn the self-management techniques can reduce or even stop their opioid use. Its about them not being afraid of their pain anymore.

Its the nature of chronic pain that the injury its warning you about, sometimes very loudly, isnt actually there. This can be seen in a persons posture as they sit and walk in a way that protects that non-injury. By gently confronting the pain, the person can eventually reclaim their normal posture and walk more confidently. Through that, they feel stronger within themselves and more in control of their pain.

The PMRI is now looking at digital support resources for people dealing with pain, Were developing an SMS based text messaging service and a more sophisticated chat-bot tool, to help people get over the hump of opioid tapering, says Glare. Its new in the pain world.

Read more:
How pain changes your brain - News - The University of Sydney